Until recently , the relatively low burden of disease in humans <*> impeded the development of coronavirus specific therapeutics .
However , the emergence of severe acute respiratory syndrome coronavirus ( SARS - CoV ) , and more recently , Middle East respiratory syndrome coronavirus ( MERS - CoV ) , has impelled the development of such drugs .
Until recently , the relatively low burden of disease in humans caused by few of these viruses impeded the development of coronavirus specific therapeutics .
However , the emergence of severe acute respiratory syndrome coronavirus ( SARS - CoV ) , and more recently , Middle East respiratory syndrome coronavirus ( MERS - CoV ) , has impelled the development of such drugs .